Filing Flows › Impact Biomedical (IBO) › Q1 2026 › vs Q4 2025
Impact Biomedical (IBO) Q1 2026 vs Q4 2025 (quarter over quarter)
Impact Biomedical's revenue rose $0 (0%) from $7K in Q4 2025 to $7K in Q1 2026.
Impact Biomedical, Q1 2026: revenue $7K, net loss $2.3M, operating cash flow −$464K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $7K | $7K | $0 | 0% |
| Other income, net | $5K | $3.8M | −$3.8M | -100% |
| Net loss | $2.3M | −$5.2M | $7.5M | — |
| Costs & expenses | $2.3M | $6.4M | −$4.1M | -64% |
| Operating costs | $2.3M | $1.2M | $1.1M | +95% |
| Research & development | $46K | $110K | −$64K | -58% |
| SG&A | $1.6M | $118K | $1.5M | 14× |
| Other operating costs | $630K | $527K | $103K | +20% |
| Operating cash sources | $2.3M | −$5.2M | $7.5M | — |
| Depreciation & amortization | $285K | $286K | −$1K | -0.3% |
| Share-based compensation | $1.4M | $8K | $1.4M | 180× |
| Working capital & other | $95K | −$5.4M | $5.5M | — |
| Cash used in operations | $464K | −$99K | $563K | — |
| Net loss absorbed | $2.3M | −$5.2M | $7.5M | — |
Questions
How much did Impact Biomedical's revenue grow quarter over quarter in Q1 2026?
Impact Biomedical's revenue rose $0 (0%) from $7K in Q4 2025 to $7K in Q1 2026.